The QCS assay for TROP2 is being implemented more broadly, at the cost of further readout delays.
ApexOnco Front Page
Recent articles
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
Intismeran autogene’s Interpath-001 trial reads out this year.
New first-in-human study initiations feature yet more in vivo Car assets.
The biotech licenses a China-developed anti-B7-H3 ADC.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
Armed with $75m the company takes a risky asset into the clinic.
GEN1286 looks dead, though MCLA-129 continues for now.
